ArticleTranslational andrology and urology2025
Comparative analysis of clinicopathological characteristics and prognostic outcomes in fumarate hydratase-deficient renal cell carcinoma versus high-grade papillary renal cell carcinoma.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Fu Zheng Xiao Yu San Jie Decoction affects the proliferation of renal cell carcinoma via regulatingTranslational andrology and urology · 2025Article
- BCL-XbioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Papillary renal cell carcinoma (pRCC) is characterized by pronounced molecular and phenotypic heterogeneity. The traditional dichotomous classification was discontinued in the 2022 World Health Organization (WHO) Fifth Edition Classification, leading to the introduction of new renal cancer categories, including fumarate hydratase (FH)-deficient renal cell carcinoma (RCC). But there remains a significant risk of misdiagnosis between FH-deficient RCC and high-grade pRCC. Furthermore, existing studies rarely provide comprehensive comparative analyses of these types of renal cancer. This study aims to investigate the clinical and pathological characteristics, as well as the prognosis, of FH-deficient RCC and high-grade pRCC, thereby providing a basis for precise diagnosis. Methods: We retrospectively analyzed the clinical and pathological data of patients diagnosed with high-grade pRCC (n=40) or FH-deficient RCC (n=20) between May 2012 and May 2023. Results: Compared to high-grade pRCC, FH-deficient RCC exhibited significant differences in several parameters: age (P<0.001), presence of necrosis (P=0.007), sarcomatoid differentiation (P=0.03), vascular cancer thrombus formation (P=0.02), lymph node metastasis (P=0.001) renal sinus invasion (P=0.042), perirenal fat invasion (P=0.01), adrenal gland invasion (P=0.003), and pathological tumor (pT) stage (P=0.009). Patients with FH-deficient tumors tended to be younger and were more likely to exhibit features such as necrosis, sarcomatoid differentiation, renal sinus and perinephric fat invasion, adrenal gland involvement, lymph node metastasis, and more advanced pathological stages compared with those with high-grade pRCC. However, FH-deficient RCC demonstrated a significantly lower incidence of lymphovascular invasion when compared to high-grade pRCC. The 3-year progression-free survival (PFS) rates were 16.9% for FH-deficient RCC and 76.2% for high-grade pRCC. Patients with FH-deficient RCC had significantly worse outcomes than those with high-grade pRCC (P<0.001). Conclusions: Patients who are younger, have advanced pathological stages, or exhibit sarcomatoid differentiation should undergo mandatory immunohistochemical staining for FH and molecular testing to prevent misdiagnosis as conventional pRCC. Despite its aggressive local behavior and poorer clinical outcomes, FH-deficient RCC shows a significantly lower frequency of vascular invasion relative to high-grade pRCC. Further investigation into the mechanisms underlying the metastasis of these tumors is warranted to identify potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.